Biomarkers in stroke have a potential challenge in the diagnosis and prognosis of stroke onset, etiology, and recovery to date. The variability of stroke, including causation, comorbidities, and lifestyle factors that affect each individual stroke survivor, is one of the key hurdles in finding biomarkers for effective acute therapies and increased long-term interventions for stroke recovery. To improve stroke diagnosis and treatment, more evidence is required to expand this list and stimulate new discoveries in determining biomarkers for stroke recovery.
In clinical practice, distinguishing between stroke subtypes and determining the time of onset are fundamental. In some patients with acute ischemic stroke, thrombolysis and thrombectomy are particularly effective therapies. Neuroimaging aids in determining who should be treated and how they should be treated, but it is costly, not always available, and has risks. Identifying blood biomarkers that represent the body's response to the damage produced by different forms of stroke is an alternate method in acute stroke diagnosis. Specific blood biomarkers capable of distinguishing ischemic stroke from hemorrhagic stroke and mimics, detecting major vascular occlusion, and predicting stroke onset time might speed up diagnosis and boost eligibility for reperfusion therapy and stroke recovery.
Thus, topic editors will welcome any types of manuscripts supported by the Journal – comprised of research article, brief research article, review, and mini-review – pertaining, but not limited to the following themes:
• Systematic reviews and meta-analyses on prognostic and diagnostic biomarkers for acute stroke
• High-throughput Proteomics approach in acute stroke biomarker discovery and validation
• Neuroimaging markers as a predictor for recurrent stroke
• Peripheral blood or cerebrospinal fluid biomarkers for stroke recovery
• Differential markers for recovery in acute and chronic stroke
Biomarkers in stroke have a potential challenge in the diagnosis and prognosis of stroke onset, etiology, and recovery to date. The variability of stroke, including causation, comorbidities, and lifestyle factors that affect each individual stroke survivor, is one of the key hurdles in finding biomarkers for effective acute therapies and increased long-term interventions for stroke recovery. To improve stroke diagnosis and treatment, more evidence is required to expand this list and stimulate new discoveries in determining biomarkers for stroke recovery.
In clinical practice, distinguishing between stroke subtypes and determining the time of onset are fundamental. In some patients with acute ischemic stroke, thrombolysis and thrombectomy are particularly effective therapies. Neuroimaging aids in determining who should be treated and how they should be treated, but it is costly, not always available, and has risks. Identifying blood biomarkers that represent the body's response to the damage produced by different forms of stroke is an alternate method in acute stroke diagnosis. Specific blood biomarkers capable of distinguishing ischemic stroke from hemorrhagic stroke and mimics, detecting major vascular occlusion, and predicting stroke onset time might speed up diagnosis and boost eligibility for reperfusion therapy and stroke recovery.
Thus, topic editors will welcome any types of manuscripts supported by the Journal – comprised of research article, brief research article, review, and mini-review – pertaining, but not limited to the following themes:
• Systematic reviews and meta-analyses on prognostic and diagnostic biomarkers for acute stroke
• High-throughput Proteomics approach in acute stroke biomarker discovery and validation
• Neuroimaging markers as a predictor for recurrent stroke
• Peripheral blood or cerebrospinal fluid biomarkers for stroke recovery
• Differential markers for recovery in acute and chronic stroke
